Trials / Completed
CompletedNCT04609020
Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment
Prospective, Multi-site Study to Evaluate Subject Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 35 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to quantify the psychological, social, and emotional impact of comprehensive aesthetic treatment with a portfolio of the Sponsor's products by measuring the change in subject's satisfaction with facial appearance from baseline (before any treatment) to the final study visit
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | JUVÉDERM | JUVÉDERM VOLBELLA with Lidocaine Treatment of any fine lines and medium-sized skin depressions. Can also be used for enhancement and pouting of the lips to correct structural defects such as asymmetry, contour deformities, volume loss. JUVÉDERM VOLIFT with Lidocaine Intended for the treatment of any deep skin depressions due to conditions such as premature aging. Can also be used for face contouring and volume restoration to correct facial structural defects such as asymmetry, contour deformities, volume loss in the lips, cheeks, chin, lower face. JUVÉDERM VOLUMA with Lidocaine Intended to restore volume of the face JUVÉDERM VOLITE with Lidocaine Intended for treatment, by filling, of superficial cutaneous depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity. JUVÉDERM VOLUX with Lidocaine Intended to restore and generate facial volume in chin and mandible areas |
| DRUG | BOTOX | Indicated for the treatment of hyperkinetic facial lines. |
| DEVICE | HArmonyCA Lidocaine | HArmonyCa Lidocaine injectable gel is a dermal filler intended for facial soft tissue augmentation. |
Timeline
- Start date
- 2023-02-15
- Primary completion
- 2024-05-10
- Completion
- 2024-05-10
- First posted
- 2020-10-30
- Last updated
- 2025-06-17
- Results posted
- 2025-06-17
Locations
6 sites across 1 country: Brazil
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04609020. Inclusion in this directory is not an endorsement.